311 related articles for article (PubMed ID: 30407325)
1. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
Li M; Mou Y; Hou S; Cao D; Li A
Medicine (Baltimore); 2018 Nov; 97(45):e13113. PubMed ID: 30407325
[TBL] [Abstract][Full Text] [Related]
2. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
Wang H; Mao C; Li N; Sun L; Zheng Y; Xu N
Medicine (Baltimore); 2019 Oct; 98(40):e17443. PubMed ID: 31577767
[TBL] [Abstract][Full Text] [Related]
3. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
4. Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report.
Wu C; Fan M; Hu Y
Anticancer Drugs; 2022 Jan; 33(1):e734-e737. PubMed ID: 34387603
[TBL] [Abstract][Full Text] [Related]
5. Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study.
Kubo T; Muramatsu J; Arihara Y; Murota A; Ishikawa K; Yoshida M; Nagashima H; Tamura F; Ikeda Y; Usami M; Ono M; Nakamura H; Watanabe D; Shibata T; Kasahara K; Sakurai A; Takada K
Jpn J Clin Oncol; 2024 Jan; 54(1):47-53. PubMed ID: 37791389
[TBL] [Abstract][Full Text] [Related]
6. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
7. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
Lohse I; Kumareswaran R; Cao P; Pitcher B; Gallinger S; Bristow RG; Hedley DW
PLoS One; 2016; 11(12):e0167272. PubMed ID: 28033382
[TBL] [Abstract][Full Text] [Related]
8. Maintenance Olaparib for Germline
Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL
N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963
[TBL] [Abstract][Full Text] [Related]
9. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
[TBL] [Abstract][Full Text] [Related]
10. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
11. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
Munroe M; Kolesar J
Am J Health Syst Pharm; 2016 Jul; 73(14):1037-41. PubMed ID: 27385701
[TBL] [Abstract][Full Text] [Related]
12. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
Lee CL; Holter S; Borgida A; Dodd A; Ramotar S; Grant R; Wasson K; Elimova E; Jang RW; Moore M; Kim TK; Khalili K; Moulton CA; Gallinger S; O'Kane GM; Knox JJ
World J Gastroenterol; 2022 Dec; 28(45):6421-6432. PubMed ID: 36533108
[TBL] [Abstract][Full Text] [Related]
13. An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer.
Prete AA; Procaccio L; Bergamo F; Rasola C; Nappo F; Zagonel V; Lonardi S
Curr Oncol; 2022 Jan; 29(2):544-550. PubMed ID: 35200549
[TBL] [Abstract][Full Text] [Related]
14. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
15. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
16. Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.
Hall JC; Marlow LA; Mathias AC; Dawson LK; Durham WF; Meshaw KA; Mullin RJ; Synnott AJ; Small DL; Krishna M; von Hoff D; Schüler J; Hart SN; Couch FJ; Colon-Otero G; Copland JA
J Transl Med; 2016 May; 14(1):129. PubMed ID: 27165126
[TBL] [Abstract][Full Text] [Related]
17. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
18. Response of
Xie Y; Jiang Y; Yang XB; Wang AQ; Zheng YC; Wan XS; Sang XT; Wang K; Zhang DD; Xu JJ; Li FG; Zhao HT
World J Gastroenterol; 2016 Dec; 22(46):10254-10259. PubMed ID: 28028375
[TBL] [Abstract][Full Text] [Related]
19. Exceptional Response of Pancreatic Acinar Cell Carcinoma and Bile Duct Cancer to Platinum-Based Chemotherapy in a Family With a Germline BRCA2 Variant.
Sunami T; Yamada A; Kondo T; Kanai M; Nagai K; Uchida Y; Yokode M; Matsumori T; Uza N; Murakami H; Yamada T; Muto M
Pancreas; 2022 Oct; 51(9):1258-1262. PubMed ID: 37078954
[TBL] [Abstract][Full Text] [Related]
20. A new targeted treatment for patients with a germline
Verdaguer H; Acosta D; Macarulla T
Future Oncol; 2020 Nov; 16(33):2691-2700. PubMed ID: 32799562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]